Study of Double Plasma Molecular Adsorption and Low-Dose Plasma Exchange in Adults With Hepatitis B-Related Acute-on-Chronic Liver Failure
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2024-11-29
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining a Double Plasma Molecular Adsorption System DPMAS with sequential low-dose plasma exchange PE to treat patients with hepatitis B virus-related acute-on-chronic liver failure ACLF. This serious liver condition has a high mortality rate, and current effective treatments are limited mainly to liver transplantation. The study aims to provide evidence for this combination therapy as a potential treatment option.
The study includes two groups one group of 100 patients will receive the combined DPMAS and low volume PE treatments along with comprehensive internal medical care. The DPMAS involves processing 5000 to 6000 milliliters of plasma, and the PE uses 1000 milliliters of fresh frozen plasma, with treatments administered three times. The other 100 patients will receive comprehensive internal medical treatment alone. This research is conducted across six medical centers.
Participants will be monitored from the start of treatment through 12 weeks. Researchers will record symptoms, signs, lab test results, adverse events, and mortality or liver transplantation rates. They will also assess changes in the Model for End-Stage Liver Disease MELD score over this period. The study focuses on safety and clinical outcomes to understand how well the combination therapy works and its impact on patients living with HBV-related ACLF.
CONDITIONS
Brief Title
Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF
Research Team
W
Wenxiong Xu, Doctor
L
Liang Peng, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical diagnosis of chronic hepatitis B virus infection (positive hepatitis B surface antigen or positive hepatitis B virus DNA for more than 0.5 year)
Age between 18 and 65 years old
Clinical diagnosis of liver failure with serum total bilirubin level greater than 10 times upper limit of normal; prothrombin time activity less than 40% and greater than or equal to 20%, or prothrombin time international ratio between 1.5 and 2.6
Platelet count greater than 50 x 10^9/L
You will not qualify if you...
Other active liver diseases
Hepatocellular carcinoma or other malignancies
Pregnancy or lactation
Human immunodeficiency virus infection or congenital immune deficiency diseases
Severe diabetes, autoimmune diseases, or unstable infarction due to cardio-cerebrovascular events
Other important organ dysfunctions or history of transplantation
Severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, or hepatorenal syndrome
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 12 weeks
Participants in the artificial liver support system group receive treatment consisting of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) three times, along with comprehensive internal medical treatment. Participants in the control group receive comprehensive internal medical treatment only.
3 treatment visits for DPMAS and PE plus additional visits for medical treatment as needed
Monitoring
Duration - 12 weeks from treatment baseline
Participants are monitored for symptoms, signs, laboratory test results, adverse events, and mortality rates from treatment baseline through 12 weeks.
Regular visits during the 12-week period for assessments
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Observational Study of Chronic Hepatitis B Virus Infection in Jiangsu
Tracking Long-Term Outcomes and Risk Factors
Observational Study on Immune Status Stages in Adults with Chronic Hepatitis B Aged 18 to 50
Evaluating TAK-242 and G-CSF With Standard Therapy for Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure in a Randomized, Placebo-Controlled Trial
Phase II Study of Injectable AS1501 for Treating Acute-on-Chronic Liver Failure in Adults Aged 18 to 75
Study of Double Plasma Molecular Adsorption and Low-Dose Plasma Exchange in Adults With Hepatitis B-Related Acute-on-Chronic Liver Failure
Comparing Two ROTEM Blood Test Thresholds to Guide Blood Transfusions
Before Invasive Procedures in Cirrhosis and Acute-on-Chronic Liver Failure
Study of CytoSorb Device Treatment in Adults with Acute on Chronic Liver Failure
Comparing Standard Care Plus CytoSorb to Standard Care Alone
Study of a Digital Liver Cancer Risk Management Program to Improve Early Diagnosis in Chinese Adults Aged 18 to 75
Evaluating Double Plasma Cytokine Adsorption With Low-Dose Plasma Exchange Versus Plasma Exchange Alone in Treating Acute-on-Chronic Liver Failure and Sepsis
Study Comparing Continuous and Pulsed PEG-Interferon Alpha-2b with Nucleostide Analogues in Treating Chronic Hepatitis B for 96 Weeks
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial.
Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure.